Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Catherine Makin

Ophthalmology New Braunfels, TX Doctor of Osteopathy

NPI 1932469251 CMS profile 1272006

218 E Austin St, New Braunfels, TX 78130

Open in the dashboard

General payments

$6,238

188 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine Makin of New Braunfels, TX is reported in the CMS Open Payments database as having received $6,238 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,484 45
2024 General $1,304 42
2023 General $1,737 30
2022 General $789 35
2021 General $767 28
2020 General $158 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Makin
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Catherine Makin were reported at $1,484. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Catherine Makin Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $158 $126 $45–$321 $114
2021 $767 $205 $76–$534 $132
2022 $789 $266 $100–$678 $149
2023 $1,737 $308 $117–$745 $160
2024 $1,304 $340 $127–$846 $164
2025 $1,484 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. TissueTech, Inc. $2,413 49 payments
  2. AbbVie, Inc. $1,270 44 payments
  3. RxSight Inc $541 9 payments
  4. Alcon Vision LLC $385 17 payments
  5. Johnson & Johnson Surgical Vision, Inc. $198 4 payments
  6. Horizon Therapeutics plc $197 12 payments
  7. Novartis Pharmaceuticals Corporation $184 10 payments
  8. Sun Pharmaceutical Industries Inc. $182 7 payments
  9. Allergan Inc. $147 7 payments
  10. Bausch & Lomb Americas Inc. $147 6 payments
  11. Other $575 23 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,203 183 payments
  2. Travel and Lodging $992 4 payments
  3. Gift $43 1 payment
Products named General payments · program years 2020–2025
  1. DURYSTA $1,070 36 payments
  2. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $435 8 payments
  3. RXSIGHT CONTACT LENS $435 8 payments
  4. LIGHT ADJUSTABLE LENS (LAL) $435 8 payments
  5. RXSIGHT INJECTOR CARTRIDGE $435 8 payments
  6. RXSIGHT INJECTOR HANDPIECE $435 8 payments
  7. PROKERA $413 17 payments
  8. AMNIOGRAFT $413 17 payments
  9. XEN GLAUCOMA TREATMENT SYSTEM $218 5 payments
  10. LUMIGAN $200 8 payments
  11. Other $2,513 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,478

Median for Ophthalmology: 891

Drug cost

$277,774

Median for Ophthalmology: $68,233

Branded share of claims

48.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 49 $70,661
Lumigan Bimatoprost Brand 84 $48,596
Cyclosporine Generic 47 $26,953
Xiidra Lifitegrast Brand 15 $23,721
Alphagan P Brimonidine Tartrate Brand 29 $13,446
Rhopressa Netarsudil Mesylate Brand 36 $12,672
Tyrvaya Varenicline Tartrate Brand 16 $10,407
Timolol Maleate Generic 123 $9,219
Combigan Brimonidine Tartrate/Timolol Brand 25 $8,784
Vyzulta Latanoprostene Bunod Brand 18 $7,511

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$453,839

Of which drugs: $79,618

Medicare patients

861

Average age 76

Services billed

3,913

506 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 34%
Diabetes 32%
Chronic kidney disease 23%
Atrial fibrillation 20%
Depression 15%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bimatoprost, intracameral implant, 1 microgram J7351 Office 27 490 $79,599

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $235
$235 — 490
TEPEZZA
  • Amgen Inc. $55
$55 — —
LUMIGAN
  • AbbVie, Inc. $44
$44 84 —
OXERVATE
  • Dompe US, Inc. $43
$43 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $30
$30 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record